Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The UK Multiple Sclerosis Risk-sharing Scheme (RSS) was established in 2002 following NICE's decision that the cost-effectiveness of interferon (IFN)-β and glatiramer acetate (GA) could not be assessed with existing short-term data. The scheme was set up as a joint undertaking between the Department of Health and the manufacturers of the drugs with input from other stakeholders. The purpose was to ensure cost-effective provision of IFNβ/GA to eligible people through a number of mechanisms, including an initial recalculation of drug pricing and the establishment of specialist nursing and medical structures. One aspect of the scheme was the enrolment of a cohort of at least 5000 people commencing IFNβ/GA with follow-up for 10 years, using these data to adjust drug costs.

Original publication

DOI

10.1136/jnnp-2013-306573.174

Type

Journal article

Journal

J Neurol Neurosurg Psychiatry

Publication Date

11/2013

Volume

84

Addresses

Newcastle upon Tyne Hospitals NHS Trust; Oxford University Hospitals NHS Trust.

Keywords

PARKINSON'S DISEASE, STROKE